Premium
Oxprenolol, methyldopa and lipids in diabetes mellitus.
Author(s) -
Benfield GF,
Hunter KR
Publication year - 1982
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1982.tb01360.x
Subject(s) - oxprenolol , medicine , methyldopa , endocrinology , triglyceride , lipoprotein , cholesterol , very low density lipoprotein , high density lipoprotein , diabetes mellitus , chemistry , blood pressure
1 Twelve‐week courses of oxprenolol and methyldopa were administered in a randomised, double‐blind cross over study to ten insulin dependent hypertensive diabetics. 2 Prior to treatment, and at the end of each period of drug administration, fasting levels of high density lipoprotein, triglycerides, free fatty acids and cholesterol were measured. 3 Neither preparation altered levels of high density lipoprotein and cholesterol, but both drugs significantly reduced the free fatty acids. 4 Whereas oxprenolol did not alter triglyceride levels, methyldopa significantly elevated triglycerides above pre‐ treatment values. 5 Oxprenolol does not appear to influence lipoprotein fractions affecting the relative risks of coronary heart disease, but methyldopa seems to have potentially detrimental effects of triglyceride levels.